Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nevro Corp (NVRO)

Nevro Corp (NVRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,330,437
  • Shares Outstanding, K 31,007
  • Annual Sales, $ 387,290 K
  • Annual Income, $ -49,210 K
  • 60-Month Beta 0.46
  • Price/Sales 11.12
  • Price/Cash Flow N/A
  • Price/Book 21.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.62
  • Number of Estimates 7
  • High Estimate -0.37
  • Low Estimate -0.86
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -93.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.24 +22.26%
on 01/15/20
140.71 -0.75%
on 02/13/20
+25.35 (+22.18%)
since 01/14/20
3-Month
103.38 +35.09%
on 11/18/19
140.71 -0.75%
on 02/13/20
+34.68 (+33.03%)
since 11/14/19
52-Week
41.25 +238.57%
on 02/22/19
140.71 -0.75%
on 02/13/20
+90.71 (+185.31%)
since 02/14/19

Most Recent Stories

More News
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?

Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.

DXCM : 283.91 (+12.57%)
HSIC : 72.13 (+0.87%)
NVRO : 139.66 (+0.19%)
TNDM : 86.03 (+3.63%)
3 Medical Product Stocks Likely to Beat This Earnings Season

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

SYK : 221.54 (+1.90%)
ABT : 89.66 (+1.11%)
BSX : 42.31 (+0.31%)
TMO : 339.19 (+1.07%)
HQY : 75.84 (+1.38%)
NVRO : 139.66 (+0.19%)
TNDM : 86.03 (+3.63%)
Sonoco (SON) Meets Q4 Earnings Estimates

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

SYK : 221.54 (+1.90%)
ABT : 89.66 (+1.11%)
BSX : 42.31 (+0.31%)
TMO : 339.19 (+1.07%)
HQY : 75.84 (+1.38%)
NVRO : 139.66 (+0.19%)
TNDM : 86.03 (+3.63%)
HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

DXCM : 283.91 (+12.57%)
HQY : 75.84 (+1.38%)
NVRO : 139.66 (+0.19%)
TNDM : 86.03 (+3.63%)
Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings

Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.

ECL : 207.31 (+0.12%)
DXCM : 283.91 (+12.57%)
HQY : 75.84 (+1.38%)
NVRO : 139.66 (+0.19%)
Medtronic (MDT) to Report Q3 Earnings: What's in Store?

In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.

MDT : 117.33 (+0.43%)
DXCM : 283.91 (+12.57%)
NVRO : 139.66 (+0.19%)
TNDM : 86.03 (+3.63%)
United States Neurology Devices Market Outlook to 2025 - Medtronic Plc, Abbott Laboratories, Nevro Corp & MicroVention Inc - ResearchAndMarkets.com

The "United States Neurology Devices Market Outlook to 2025 - Hydrocephalus shunts, Interventional Neuroradiology, Minimally Invasive Neurosurgery and Others." report has been added to ResearchAndMarkets.com's...

ABT : 89.66 (+1.11%)
MDT : 117.33 (+0.43%)
NVRO : 139.66 (+0.19%)
Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?

Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.

CVS : 71.37 (-0.87%)
DXCM : 283.91 (+12.57%)
NVRO : 139.66 (+0.19%)
TNDM : 86.03 (+3.63%)
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

DXCM : 283.91 (+12.57%)
NVRO : 139.66 (+0.19%)
TNDM : 86.03 (+3.63%)
CGC : 22.13 (+13.37%)
Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings

Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter

DXCM : 283.91 (+12.57%)
NVRO : 139.66 (+0.19%)
TNDM : 86.03 (+3.63%)
CGC : 22.13 (+13.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVRO with:

Business Summary

Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza...

See More

Key Turning Points

2nd Resistance Point 142.20
1st Resistance Point 140.93
Last Price 139.66
1st Support Level 137.88
2nd Support Level 136.11

See More

52-Week High 140.71
Last Price 139.66
Fibonacci 61.8% 102.72
Fibonacci 50% 90.98
Fibonacci 38.2% 79.24
52-Week Low 41.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar